

9 April 2026

CARETEQ COMPLETES SALE OF EMBEDDED HEALTH SOLUTIONS

Careteq Limited (ASX: CTQ) (“Careteq” or “the Company”), is pleased to announce completion of the sale of its fully owned subsidiary, Embedded Health Solutions (EHS) to Nationwide Investments Holdings Pty Ltd.

Refer to the ASX Release dated 6 February 2026 titled “Careteq Signs Binding Agreement for Divestment of Embedded Health Solutions”.

Consideration Received

The Business and asset sale agreement entered into for the divestment of EHS was for \$5m less customary purchase price adjustments. These adjustments were represented by working capital adjustments and employee entitlement liabilities for all transferring employees, the combined adjustment amounting to approximately \$990k.

Use of Net Funds

In August 2024, Careteq entered into a vendor loan agreement with the minority shareholders of Embedded Health Solutions where the Company announced the acquisition of the remaining 45% of Embedded Health Solutions from its minority shareholder. The vendor loan has now been fully paid including all outstanding interest amounting to approximately \$2.47m from the settlement proceeds.

The net proceeds from the sale are intended to be utilised to focus on the growth of the Careteq’s market place platform HMR Referrals now that the Company’s balance sheet has been relieved of a material liability and is better positioned to defend its position against the ATO, and its current R&D claims whilst going through the formal objection process with the ATO.

ASX Requirements

As communicated when the sale was announced in February 2026, a disposal by a listed entity of its main undertaking can raise issues under ASX Listing Rule 12.1 and 12.2, which oblige a listed entity to satisfy ASX on an ongoing basis that the level of its operations is sufficient, and its financial condition adequate, to warrant its continued quotation of its securities.

ASX have advised that Careteq will be afforded a period of 6 months from the date of the agreement of the disposal of its interest in Embedded Health Solutions (by 6 August 2026) to demonstrate to the ASX that it is compliant with Listing Rule 12.1.

The ASX also advises that if Careteq does not demonstrate compliance with this Rule to ASX’s satisfaction by the 6-month anniversary, ASX will suspend trading in its securities. The consequences of a disposal of the main undertaking are that any transaction Careteq proposes to enter into may, if required by ASX, attract the application of Listing Rule 11.1.3 and as a result the Company may, if required by ASX, be required to re-comply with Chapters 1 and 2 of the Listing Rules.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)**For further information, please contact:****Careteq Limited (ASX: CTQ)**

Mark Simari
Executive Chairman
P: +61 3 8866 5594
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative medication management solutions. The Company is dedicated to improving healthcare outcomes through its fully owned HMR Referrals platforms. HMR Referrals streamlines Home Medicines Reviews (HMRs) for the home care and disability sector.

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>